Repligen | RGEN - PE价格收益



金融业
股票价格
USD
资产
USD 2.93B
现金及等价物
USD 582.65M
销售成本
USD 85.97M
流动资产
USD 1.16B
流动负债
USD 126.21M
债务
USD 546.59M
EBIT
USD 19.98M
EBITDA
USD 40.01M
员工
1.78K
EPS每股收益
USD 0.48
股本和储备
USD 2.11B
销售毛利
USD 108.28M
债务利息支出
USD 5.58M
利息收入
USD 7.31M
贷款资金
USD 546.59M
市值
USD 6.32B
净收入
USD 8.33M
营业费用
USD 174.27M
营业利润
USD 19.98M
普通股股本
USD 56.4M
PE价格收益
109.48
税前利润
USD 19.11M
销售收入
USD 194M
销售和管理费用
USD 76.54M
股票
USD 179.26M
贸易债权人
USD 34.66M
应收帐款人
USD 151.55M


Pe 更改 日
Agilent 25.04 2.13 2025-12
Align Technology 22.78 3.05 2026-03
Bio Techne 38.75 81.27 2026-03
BioMarin Pharmaceutical 15.28 3.96 2026-03
Bristol-Myers Squibb 9.08 0.2 2026-03
Bruker 36.79 44.56 2026-03
Charles River Laboratories 29.26 14.31 2026-03
Danaher 29.29 10.39 2026-03
Dentsply International 20.31 9.68 2026-03
General Electric Aerospace 34.26 4.95 2026-03
Henry Schein 16.89 1.54 2026-03
Illumina 32.45 2.07 2026-03
IQVIA Holdings 19.37 7.21 2026-03
Mettler Toledo International 27.34 5.07 2026-03
OraSure Technologies 24.42 12.6 2024-09
Pfizer 9.32 5.16 2026-03
Repligen 109.48 54.58 2026-03
Revvity 30.79 19.08 2026-03
Thermo Fisher Scientific 27.71 3.29 2026-03
Waters 29.75 5.54 2026-03
West Pharmaceutical Services 31.99 5.76 2026-03